This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Prevalence and risk factors of having antibodies to class I and II human leukocyte antigens in older haploidentical allograft candidates
Scientific Reports Open Access 11 February 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.
Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS et al. Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia. Blood 2015; 126: 1033–1040.
Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013; 31: 1310–1316.
Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF et al. Comparison of outcomes following peripheral blood haploidentical vs matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center review. Biol Blood Marrow Transplant 2016; 22: 1696–1701.
Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009; 88: 1019–1024.
Ciurea SO, Thall PF, Wang X, Wang Sa, Hu Y, Cano P et al. Donor-specific anti-HLAAbs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011; 118: 5957–5964.
Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010; 115: 2704–2708.
Chang YJ, Zhao XY, Xu LP, Zhang XH, Wang Y, Han W et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol 2015; 8: 84.
Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012; 47: 508–515.
Gladstone DE, Zachary AA, Fuchs EJ, Luznik L, Kasamon YL, King KE et al. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant 2013; 19: 647–652.
Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y et al. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2015; 21: 1–7.
Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487–1496.
Taylor PA, Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007; 109: 1307–1315.
Armand P, Kim H, Logan B . Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood 2014; 123: 3664–3672.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT) –specific comorbidity index : a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.
Acknowledgements
The research reported in this publication was supported by the Washington University Institute of Clinical and Translational Sciences grant UL1TR000448, sub-award TL1TR000449, from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH. We would like to acknowledge Kathryn Trinkaus, PhD, for her work on the statistical analysis for this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Zou, J., Romee, R., Slade, M. et al. Untreated donor specific antibodies against HLA are associated with poor outcomes in peripheral blood haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 52, 898–901 (2017). https://doi.org/10.1038/bmt.2017.7
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.7
This article is cited by
-
Effects of donor-specific antibodies on engraftment and long-term survival after allogeneic hematopoietic stem cell transplantation—A systematic review and meta-analysis
Bone Marrow Transplantation (2023)
-
Prevalence and risk factors of having antibodies to class I and II human leukocyte antigens in older haploidentical allograft candidates
Scientific Reports (2020)